期刊文献+

老年维持性血液透析患者矿物质代谢相关影响因素分析 被引量:8

Study on the related factors for mineral metabolism in elderly patients with maintenance hemodialysis
原文传递
导出
摘要 目的探讨老年维持性血液透析(MHD)患者矿物质代谢现况及相关影响因素,以提高本地区老年MHD患者生活质量和生存率。方法收集2012年1月至2013年8月新乡往电医4家综合医院466例MHD治疗3个月及以上患者的临床资料,按年龄将其分为老年组(年龄≥60岁)159例和非老年组(年龄〈60岁)307例。检测所有患者的血清钙离子、磷、全段甲状旁腺激素(iPTH)及碱性磷酸酶(ALP)等矿物质代谢的评估指标。分析老年MHD患者矿物质代谢现况及其与贫血:透析龄、透析充分性、营养不良及炎症因子等因素的关系。结果466例患者中,血钙(1.95±0.34)mmol/L,血磷(2.54±1.38)mmol/L,iPTH(409.5±345.6)ng/L;钙、磷和iPTH达标率分别为34.3%、20.4%和25.5Voo,每周透析3次患者的钙、磷和iPTH达标率分别’为50.8%、31.重%和32.2%。老年组患者血磷、iPTH、ALP、白蛋白、转铁蛋白饱和度低于非老年组(均P〈0.01),前白蛋白、血红蛋白、铁蛋白亦低于非老年组(均P〈0.05);而血钙、C反应蛋白明显高于非老年组(均P〈0.05)。结论老年MHD患者矿物质代谢异常有其独特的临床变化,主要表现为低转运骨病,存在微炎症、营养不良,且贫血较非老年MHD患者更为严重。 Objective To investigate the present state of mineral metabolism and its related factors in elderly patients with maintenance hemodialysis (MHD), in order to improve the quality of life and survival rate in elderly patients with MHD in Xinxiang. Methods Clinical data of 466 patients with treatment of MHD for over 3 months in 4 hospitals in Xinxiang distxict were enrolled from January 2012 to August 2013 in this study, and the patients were divided into the elderly group (n=159, aged ≥60 years) and the non-elderly group (n= 307, aged〈60 years). The evaluation indexes for mineral metabolism were determinated, such as serum levels of calcium, phosphorus, intact parathyroid hormone (iPTH) and alkaline phosphatase (ALP). The present state of mineral metabolism and its relationships with anemia, dialysis ages, adequacy of dialysis, malnutrition and inflammatory factors were analyzed in elderly patients with MHD. Results Among 466 patients, the serum levels of calcium, phosphorus and iPTH in MHD patients were (1. 95±0. 34) retool/L, (2.54±1.38) mmol/L and (409.5±345.6) ng/L respectively, and their control rates were 34.3%, 20.4% and 25.5% respectively. And in patients with hemodialysis three times a week, the control rates were 50.8%, 31.4% and 32.2% respectively. The serum levels of phosphorus, iPTH, ALP, albumin and transferrin saturation were lower in elderly group than in non-elderly group (all P〈0.01), and the serum levels of pre-alhumin, hemoglobin and feritin were lower in elderly group than in non-elderly group (all P〈0.05). But the serum levels of calcium and C-reactive protein (CRP) were higher in elderly group than in non-elderly group (all P〈0.05). Conclusions The elderly patients with MHD exhibit unique clinical manifestations of abnormal mineral metabolism, and low bone transformation osteopathy is the main manifestation. The micro-inflammation, malnutrition and anemia are more severe in elderly patients than in non-elderly patients.
出处 《中华老年医学杂志》 CAS CSCD 北大核心 2015年第10期1094-1098,共5页 Chinese Journal of Geriatrics
基金 新乡市重点科技攻关计划项目,河南省卫生科技创新型人才工程专项经费资助课题
关键词 血液透析滤过 肾性骨营养障碍 钙代谢障碍 甲状旁腺素 Hemodiafiltration Renal osteodystrophy Calcium metabolism disorders Phosphorus Parathyroid hormone
  • 相关文献

参考文献15

  • 1Levin A.Bakris GL,Molitch M,et al. Prevalence ofabnormal serum vitamin D,PTH, calcium andphosphorus in patients with chronic kidney disease:results of the study to evaluate early kidney disease[J]. Kidney Int, 2007,71:31-38.
  • 2Kidney Disease; Improving Global Outcomes(KDIGO) CKD-MBD Work Group. KDIGO clinicalpractice guideline for the diagnosis, evaluation.prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)[J]. KidneyInt Suppl, 2009,113:SM30.
  • 3Kendric J. Chonchol M. The role of phosphorus inthe development and progression of vascularcalcification [ J ] . Am J Kidney Dis,2011, 58:826-834.
  • 4Adeney KL, Siscovick DS,Ix JH, et al. Associationof serum phosphate with vascular and valvularcalcification in moderate CKD [ J ] . J Am SocNephrol, 2009,20*381-387.
  • 5Kong X,Zhang L,Zhang L, et al. Mineral and bonedisorder in Chinese dialysis patients : a multicenterstudy[J]. BMC Nephrol, 2012,13:116.
  • 6王伟,方静,董俊邑,梁江红,郁昊,卢小琼.维持性血液透析患者钙磷代谢异常调查[J].实用医院临床杂志,2010,7(2):75-78. 被引量:6
  • 7顾波,路建饶,易扬,王汉青,宣怡.老年2型糖尿病肾病维持性血液透析患者的骨代谢研究[J].中国血液净化,2011,10(8):440-443. 被引量:6
  • 8Palmer SC, Hayen A,Macaskill P,et al. Serumlevels of phosphorus,parathyroid hormone. andcalcium and risks of death and cardiovascular diseasein individuals with chronic kidney disease: asystematic review and meta-analysis [ J ] . JAMA,2011, 305:1119-1127.
  • 9Floege J,Kim J,Ireland E,et al. Serum iPTH,calcium and phosphate,and the risk of mortality in aEuropean hemodialysis population[J]. Nephrol DialTransplant, 2011,26:1948-1955.
  • 10Jean G, Lataillade D,Genet L,et al. Associationbetween very low PTH levels and poor survival raresin hemodialysis patients: results from the FrenchARNOS cohort[J]. Nephron Clin Pract, 2011.118:211-216.

二级参考文献31

  • 1Thanh-Mai Vo,Sinee Disthabanchong.Are there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease?[J].World Journal of Cardiology,2014,6(5):216-226. 被引量:5
  • 2孙鲁英,王梅,杨莉.终末期肾脏病患者钙磷代谢及甲状旁腺激素水平的临床分析[J].北京大学学报(医学版),2005,37(2):147-150. 被引量:63
  • 3Block G, Port FK. Calcium phosphate metabolism and cardiovascular disease in patients with chronic kidney disease [ J]. Semin Dial,2003,16 (1) : 140-147.
  • 4Moe SM, O'Neill KD, Fiueberg N, et al. Assessment of vascular calcification in ESRD patients using spiral CT[J]. NDT, 2003,18 ( 11 ) : 1152- 1158.
  • 5Foley RN, Parfrey PS, Harnett JD, et al. Hypocalemia, morbidity, and mortality in end -stage renal disease [ J ]. Am J Nephrol, 1996,16 (3) : 386- 393.
  • 6Block GA, Hulbert-Shearron TE, Levin NW, et aL Association of serum phosphorus and calcium, phosphate product with mortality in chronic hemodialysis patients:A national study [J]. Am J Kidney Dis, 1998,31 (6) : 607-617.
  • 7Goodman WG, Golddin J, Kuizon BD, et al. Coronary-artery calcification in young adults with endstage renal who are undergoing dialysis [ J]. N Engl J Med,2000,342( 13 ) : 1478-1483.
  • 8Masho Y, Shigematsu T. Arteriosclerosis and vascular calcification in chronic kidney disease patients [ J ] . ClinCalcium,2007,17 ( 3 ) :354-359.
  • 9Georg S,Thilo K,Zivka D, et al. Vascular access calcification predicts mortality in hemodialysis patients [ J ]. Kidney International, 2008,74 (14) : 1582-1587.
  • 10Cozzoliino M, Brancaccio D. Emerging role for the vitamin D recepter activator, paricalcitol, in the treatment of secondary hyperparathyroidism[ J ]. Expert Opin Pharmacother,2008,9( 8 ) :947-954.

共引文献48

同被引文献57

引证文献8

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部